TerminatedPhase 4

Efficacy and Safety of Ferriprox® in Patients With Sickle Cell Disease or Other Anemias

Stopped: Difficulties with additional recruitment as pool of potential patients was exhausted, and sufficient information for determination of study outcome measure was already obtained

United States230 participantsStarted 2014-04-17

Plain-language summary

This research is being done so that we can look at the safety and efficacy of deferiprone in people with sickle cell disease or other anemias. Deferiprone is a drug that removes iron from the body. We will be comparing deferiprone with deferoxamine, another drug that removes iron from the body.

Who can participate

Age range2 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion criteria

✓. Male or female ≥ 2 years of age;

Exclusion criteria

✕. Baseline LIC \>7 mg/g dw (measured by MRI);
✕. Patients who have received no less than 20 transfusions of RBCs;
✕. Patients who have received at least 1 transfusion per year in the last 2 years and who are expected to have a continuing requirement (based on Investigator's judgement) during the duration of the trial
✕. Thalassemia syndromes;
✕. Myelodysplastic syndrome (MDS) or myelofibrosis;
✕. Diamond Blackfan anemia;
✕. Primary bone marrow failure;
✕. Baseline LIC \>30 mg/g dw (measured by MRI);

What they're measuring

Change From Baseline in Liver Iron Concentration (LIC)

Timeframe: Change from baseline to Week 52

Trial details

NCT IDNCT02041299

SponsorApoPharma

Sponsor typeINDUSTRY

Study typeINTERVENTIONAL

Primary completion2019-04-20

Results submitted2021-05-13

View on ClinicalTrials.gov More Iron Overload trials